Advanced Filters
noise

Rockville, Maryland Clinical Trials

A listing of Rockville, Maryland clinical trials actively recruiting patient volunteers.

Found 739 clinical trials
R Robert J. Kreitman

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a …

18 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Cardamom and Topical Roseomonas in Atopic Dermatitis

Background Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems. No cure exists for AD. Researchers know that people with AD have …

2 - 100 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective To find out if atorvastatin reduces hearing loss in people …

18 - 100 years of age All Phase 2
L Lisa Ley

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want …

18 - 120 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Background The blood-brain barrier separates the brain from the rest of the body. Epilepsy is a neurological disease that causes seizures. It can affect this barrier. Researchers think a contrast agent called mangafodipir might be better able to show areas of the brain that epilepsy affects. Objective To see if …

18 - 60 years of age All Phase 1
N National Cancer Institute Referral Office

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Background Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body. Many of these cancers have a high risk of relapse and a low chance of survival. Better treatments are needed. Objective To test a new drug, ADCT-701, in people …

18 - 120 years of age All Phase 1

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.

18 years of age All Phase 1

To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment …

18 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

Background Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to …

18 - 100 years of age All Phase N/A

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

18 years of age All Phase 1/2

Simplify language using AI